Tag Archive | "biotechnology"

Bavarian Nordic: Biotechnology partnering activity 2009-2014

Tags: , , ,


Bavarian Nordic is an international biotechnology headquartered in Denmark. Read the full story

Bavarian Nordic: Biotechnology smallpox fighters

Tags: , ,


Bavarian Nordic is a biotechnology company developing and manufacturing therapeutics for cancer and infectious diseases. Read the full story

Bavarian Nordic Pharmaceuticals: M&A activity

Tags: , ,


Bavarian Nordic Pharmaceuticals has announced only 1 M&A deal since 2009; the acquisition of BN Immuno Therapeutics. Read the full story

Co-development agreement for malaria vaccine

Tags: , ,


ARTES Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI). Read the full story

Galapagos – Rapidly taking identified targets through to clinical development

Tags: , ,


Galapagos is a clinical stage biotechnology company headquartered in Belgium discovering and developing candidates to phase I/II development. Read the full story

Galapagos: Biotechnology Partnering activity 2009-2014

Tags: , , , ,


Galapagos, a clinical stage biotechnology company in the United States, is a joint venture between Crucell and Tibotec. Read the full story

Galapagos: M&A activity 2009-2014

Tags: , , ,


Galapagos has acquired only one company since 2009 with the acquisition of Cangenix. Read the full story

Actelion: Conducting sophisticated partnerships only

Tags: , ,


Actelion is a Switzerland based biopharmaceutical company discovering, developing and commercializing products for unmet medical needs. Read the full story

Actelion: Partnering activity 2009-2014

Tags: , ,


Actelion, a big biotech company based in Switzerland, has a fully integrated business model focused on innovative treatments to serve high unmet medical needs. Read the full story

Human Genome Most Lucrative on Record Biotechnology Premiums

Tags: , ,


In an age of medicines losing patents & drug makers in search for new therapies, biotechnology firms are concernned about  the increasing takeover premiums Read the full story